Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation.

Trial Profile

Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Aug 2016

At a glance

  • Drugs Pioglitazone (Primary)
  • Indications Allotransplant rejection; Insulin resistance
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Jul 2016 Status changed from active, no longer recruiting to completed.
    • 27 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 27 Mar 2013 Planned end date changed from 1 Jun 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top